Robert A. Sershon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert A. Sershon has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Craig J. Della Valle
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL
7 shared publicationsBrett R. Levine
Medstar Georgetown University, Department of Orthopaedic Surgery, Washington, District of Columbia
6 shared publications- Daniel D. Bohl
Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA
5 shared publications - Anthony A. Romeo
Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, IL, USA
4 shared publications Brian J. Cole
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA
4 shared publications- Craig J. Della Valle
Department of Orthopaedics, Rush University Medical Center, Chicago, IL 60612
3 shared publications
Latest Publications
- 16 October 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
What Motion Is For
Was not provided for this article.
- 16 October 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
What Motion Is For
Was not provided for this article.
- 28 March 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 76, 215-221
Do perioperative efficiency changes compromise patient outcomes in primary hip and knee arthroplasty?
- 28 March 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 76, 215-221
Do perioperative efficiency changes compromise patient outcomes in primary hip and knee arthroplasty?
- 20 May 2025
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40  (9) , S41-S48
Pelvic Reconstruction for Complex Bone Defects in Revision Total Hip Arthroplasty
- 20 May 2025
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 40  (9) , S41-S48
Pelvic Reconstruction for Complex Bone Defects in Revision Total Hip Arthroplasty
- 3 December 2024
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483  (3) , 429-430
CORR Insights®: Is 18F-fluoride PET/CT an Accurate Tool to Diagnose Loosening After Total Joint Arthroplasty?
- 3 December 2024
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 483  (3) , 429-430
CORR Insights®: Is 18F-fluoride PET/CT an Accurate Tool to Diagnose Loosening After Total Joint Arthroplasty?
- 1 September 2024
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 106-B  (9) , 916-923
Outcomes of fixed versus mobile-bearing medial unicompartmental knee arthroplasty
Aims: The optimal bearing surface design for medial unicompartmental knee arthroplasty (UKA) remains controversial. The aim of this study was to compare outcomes of fixed-bearing (FB) and mobile-bearing (MB) UKAs from a single high-volume institution.Methods: Prospectively collected data were reviewed for all primary cemented medial UKAs performed by seven surgeons from January 2006 to December 2022. A total of 2,999 UKAs were identified, including 2,315 FB and 684 MB cases. The primary outcome measure was implant survival. Secondary outcomes included 90-day and cumulative complications, reoperations, component revisions, conversion arthroplasties, range of motion, and patient-reported outcome measures. Overall mean age at surgery was 65.7 years (32.9 to 94.3), 53.1% (1,593/2,999) of UKAs were implanted in female patients, and demographics between groups were similar (p > 0.05). The mean follow-up for all UKAs was 3.7 years (0.0 to 15.6).Results: Using revision for any reason as an endpoint, five-year survival for FB UKAs was 97.2% (95% CI 96.4 to 98.1) compared to 96.0% for MB (95% CI 94.1 to 97.9; p = 0.008). The FB group experienced fewer component revisions (14/2,315, 0.6% vs 12/684, 1.8%; p < 0.001) and conversion arthroplasties (38/2315, 1.6% vs 24/684, 3.5%; p < 0.001). A greater number of MB UKAs underwent revision due to osteoarthritis progression (FB = 21/2,315, 0.9% vs MB = 16/684, 2.3%; p = 0.003). In the MB group, 12 (1.8%) subjects experienced bearing dislocations which required revision surgery. There were 15 early periprosthetic tibia fractures (0.6%) in the FB group compared to 0 for MB (p = 0.035).Conclusion: In similar patient populations, FB UKAs demonstrated slightly higher survival than a commonly used MB design. Adverse event profiles differed by bearing type, with an increased risk of bearing dislocation and OA progression with MB designs, and early periprosthetic tibia fractures for FB designs.Cite this article: Bone Joint J 2024;106-B(9):916–923.
- 1 September 2024
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 106-B  (9) , 916-923
Outcomes of fixed versus mobile-bearing medial unicompartmental knee arthroplasty
Aims: The optimal bearing surface design for medial unicompartmental knee arthroplasty (UKA) remains controversial. The aim of this study was to compare outcomes of fixed-bearing (FB) and mobile-bearing (MB) UKAs from a single high-volume institution.Methods: Prospectively collected data were reviewed for all primary cemented medial UKAs performed by seven surgeons from January 2006 to December 2022. A total of 2,999 UKAs were identified, including 2,315 FB and 684 MB cases. The primary outcome measure was implant survival. Secondary outcomes included 90-day and cumulative complications, reoperations, component revisions, conversion arthroplasties, range of motion, and patient-reported outcome measures. Overall mean age at surgery was 65.7 years (32.9 to 94.3), 53.1% (1,593/2,999) of UKAs were implanted in female patients, and demographics between groups were similar (p > 0.05). The mean follow-up for all UKAs was 3.7 years (0.0 to 15.6).Results: Using revision for any reason as an endpoint, five-year survival for FB UKAs was 97.2% (95% CI 96.4 to 98.1) compared to 96.0% for MB (95% CI 94.1 to 97.9; p = 0.008). The FB group experienced fewer component revisions (14/2,315, 0.6% vs 12/684, 1.8%; p < 0.001) and conversion arthroplasties (38/2315, 1.6% vs 24/684, 3.5%; p < 0.001). A greater number of MB UKAs underwent revision due to osteoarthritis progression (FB = 21/2,315, 0.9% vs MB = 16/684, 2.3%; p = 0.003). In the MB group, 12 (1.8%) subjects experienced bearing dislocations which required revision surgery. There were 15 early periprosthetic tibia fractures (0.6%) in the FB group compared to 0 for MB (p = 0.035).Conclusion: In similar patient populations, FB UKAs demonstrated slightly higher survival than a commonly used MB design. Adverse event profiles differed by bearing type, with an increased risk of bearing dislocation and OA progression with MB designs, and early periprosthetic tibia fractures for FB designs.Cite this article: Bone Joint J 2024;106-B(9):916–923.
- 15 February 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39  (9) , S60-S64
Advanced Concepts in Outpatient Joint Arthroplasty
- 15 February 2024
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 39  (9) , S60-S64
Advanced Concepts in Outpatient Joint Arthroplasty
- 18 December 2023
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 482  (2) , 311-312
CORR Insights®: Robotic-assisted TKA is Not Associated With Decreased Odds of Early Revision: An Analysis of the American Joint Replacement Registry
- 18 December 2023
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 482  (2) , 311-312
CORR Insights®: Robotic-assisted TKA is Not Associated With Decreased Odds of Early Revision: An Analysis of the American Joint Replacement Registry
- 28 September 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102  (21) , 1883-1890
The Optimal Dosing Regimen for Tranexamic Acid in Revision Total Hip Arthroplasty
Background: The purpose of this multicenter, randomized trial was to determine the optimal dosing regimen of tranexamic acid (TXA) to minimize perioperative blood loss in revision total hip arthroplasty. Methods: Six centers prospectively randomized 175 patients to 1 of 4 regimens: (1) 1-g intravenous (IV) TXA prior to incision (the single-dose IV group), (2) 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (the double-dose IV group), (3) a combination of 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (the combined IV and topical group), or (4) 3 doses totaling 1,950-mg oral TXA (the multidose oral group). Randomization was based on revision subgroups to ensure equivalent group distribution. An a priori power analysis (α = 0.05; β = 0.80) determined that 40 patients per group were required to identify a >1-g/dL difference in postoperative hemoglobin reduction between groups. Per-protocol analysis involved an analysis of variance, Fisher exact tests, and two 1-sided t tests for equivalence. Demographic and surgical variables were equivalent between groups. Results: No significant differences were found between TXA regimens when evaluating reduction in hemoglobin (3.4 g/dL for the single-dose IV group, 3.6 g/dL for the double-dose IV group, 3.5 g/dL for the combined IV and topical group, and 3.4 g/dL for the multidose oral group; p = 0.95), calculated blood loss (p = 0.90), or transfusion rates (14% for the single-dose IV group, 18% for the double-dose IV group, 17% for the combined group, and 17% for the multidose oral group; p = 0.96). Equivalence testing revealed that all possible pairings were statistically equivalent, assuming a >1-g/dL difference in hemoglobin reduction as clinically relevant. There was 1 venous thromboembolism, with no differences found between groups (p = 1.00). Conclusions: All 4 TXA groups tested had equivalent blood-sparing properties in the setting of revision total hip arthroplasty, with a single venous thromboembolism reported in this high-risk population. Based on the equivalence between groups, surgeons should utilize whichever of the 4 investigated regimens is best suited for their practice and hospital setting. Given the transfusion rate in revision total hip arthroplasty despite TXA utilization, further work is required in this area. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- 28 September 2020
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102  (21) , 1883-1890
The Optimal Dosing Regimen for Tranexamic Acid in Revision Total Hip Arthroplasty
Background: The purpose of this multicenter, randomized trial was to determine the optimal dosing regimen of tranexamic acid (TXA) to minimize perioperative blood loss in revision total hip arthroplasty. Methods: Six centers prospectively randomized 175 patients to 1 of 4 regimens: (1) 1-g intravenous (IV) TXA prior to incision (the single-dose IV group), (2) 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (the double-dose IV group), (3) a combination of 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (the combined IV and topical group), or (4) 3 doses totaling 1,950-mg oral TXA (the multidose oral group). Randomization was based on revision subgroups to ensure equivalent group distribution. An a priori power analysis (α = 0.05; β = 0.80) determined that 40 patients per group were required to identify a >1-g/dL difference in postoperative hemoglobin reduction between groups. Per-protocol analysis involved an analysis of variance, Fisher exact tests, and two 1-sided t tests for equivalence. Demographic and surgical variables were equivalent between groups. Results: No significant differences were found between TXA regimens when evaluating reduction in hemoglobin (3.4 g/dL for the single-dose IV group, 3.6 g/dL for the double-dose IV group, 3.5 g/dL for the combined IV and topical group, and 3.4 g/dL for the multidose oral group; p = 0.95), calculated blood loss (p = 0.90), or transfusion rates (14% for the single-dose IV group, 18% for the double-dose IV group, 17% for the combined group, and 17% for the multidose oral group; p = 0.96). Equivalence testing revealed that all possible pairings were statistically equivalent, assuming a >1-g/dL difference in hemoglobin reduction as clinically relevant. There was 1 venous thromboembolism, with no differences found between groups (p = 1.00). Conclusions: All 4 TXA groups tested had equivalent blood-sparing properties in the setting of revision total hip arthroplasty, with a single venous thromboembolism reported in this high-risk population. Based on the equivalence between groups, surgeons should utilize whichever of the 4 investigated regimens is best suited for their practice and hospital setting. Given the transfusion rate in revision total hip arthroplasty despite TXA utilization, further work is required in this area. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- 1 February 2020
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 35  (2) , 353-357
The Impact of Coronal Alignment on Revision in Medial Fixed-Bearing Unicompartmental Knee Arthroplasty
- 1 February 2020
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 35  (2) , 353-357
The Impact of Coronal Alignment on Revision in Medial Fixed-Bearing Unicompartmental Knee Arthroplasty
- 1 December 2019
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 34  (12) , 2861-2865
Outpatient Total Hip Arthroplasty Performed at an Ambulatory Surgery Center vs Hospital Outpatient Setting: Complications, Revisions, and Readmissions
- 1 December 2019
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 34  (12) , 2861-2865
Outpatient Total Hip Arthroplasty Performed at an Ambulatory Surgery Center vs Hospital Outpatient Setting: Complications, Revisions, and Readmissions